[
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
    "title": "Kvartalsrapport Q1 2026",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a17a9a42943519ac9b9499fe483dd8fb0",
    "date": "2026-05-06",
    "period": "2026-q1",
    "form_type": "interim-report",
    "report_key": "2026:q1",
    "filename": "Delarsrapport_Q1_2026.pdf",
    "text_chars": 43334,
    "sha256": "09147e95128f9573312939d88e4cd55ef0f44869b0d6c2e67669fdb18de078a2",
    "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
        "chars": 43334
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2025",
    "title": "Årsredovisning 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ac8734d7900ed05a77157d57e58b8b371",
    "date": "2026-03-26",
    "period": "2025-annual",
    "form_type": "annual-report",
    "report_key": "2025:annual",
    "filename": "Vicore_Arsredovisning_2025.pdf",
    "text_chars": 264632,
    "sha256": "cf21b11fe94cda4920e011e4e767df699b1349e5f5e2c869b360c68369924dd6",
    "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025",
    "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
        "chars": 177351
      },
      {
        "number": 2,
        "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
        "chars": 87279
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
    "title": "Kvartalsrapport Q4 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/afd2d355616d2dcdf9003f1247ed96a80",
    "date": "2026-02-27",
    "period": "2025-q4",
    "form_type": "year-end-report",
    "report_key": "2025:q4",
    "filename": "Bokslutskommunike_2025.pdf",
    "text_chars": 48919,
    "sha256": "7e4a990abee0deb5b338104e95f47947087f925b89faba7d499c506c37cc4b57",
    "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
        "chars": 48919
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
    "title": "Kvartalsrapport Q3 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a29e802aad5879985f414115f16438495",
    "date": "2025-11-05",
    "period": "2025-q3",
    "form_type": "interim-report",
    "report_key": "2025:q3",
    "filename": "Delarsrapport_Q3_2025.pdf",
    "text_chars": 51972,
    "sha256": "0e5199bb265cc9be60565f6340f00d5a45b86ab1b999286b68a23102291bd697",
    "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
        "chars": 51972
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
    "title": "Kvartalsrapport Q2 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a601e14263c6a6dcc72f09a601e5b2ca5",
    "date": "2025-08-22",
    "period": "2025-q2",
    "form_type": "interim-report",
    "report_key": "2025:q2",
    "filename": "Delarsrapport_Q2_2025.pdf",
    "text_chars": 46643,
    "sha256": "4f5e331a70cc9772f9dd39e6df020504fac3d16ca61251bf208d4a16873d736a",
    "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
        "chars": 46643
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
    "title": "Kvartalsrapport Q1 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ad1ca81c15c657972c0cbda55b9a6cf97",
    "date": "2025-05-06",
    "period": "2025-q1",
    "form_type": "interim-report",
    "report_key": "2025:q1",
    "filename": "Delarsrapport_1_Jan_31_Mar_2025.pdf",
    "text_chars": 45176,
    "sha256": "161203666816ea945e02334a7230bae78a4e1ea2e6b137545068c9a8eaa7c3c3",
    "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
        "chars": 45176
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2024",
    "title": "Årsredovisning 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a66794ceb802528c55ffb3b1ee8c7dc30",
    "date": "2025-03-26",
    "period": "2024-annual",
    "form_type": "annual-report",
    "report_key": "2024:annual",
    "filename": "Vicore_Arsredovisning_2024.pdf",
    "text_chars": 287791,
    "sha256": "e628a6484cb38d6916f50f4bc7eb4107854107a6b4209198279eeffc4e890f83",
    "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024",
    "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
        "chars": 177393
      },
      {
        "number": 2,
        "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
        "chars": 110396
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
    "title": "Kvartalsrapport Q4 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ae73c8303818455588695b9a0c1a06058",
    "date": "2025-02-27",
    "period": "2024-q4",
    "form_type": "year-end-report",
    "report_key": "2024:q4",
    "filename": "Bokslutskommunike_2024_SWE.pdf",
    "text_chars": 49883,
    "sha256": "d4ea4a7ef8edb2a85eb7b43efde15f54c7399e3b60bc62edffc2942f1effadfd",
    "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
        "chars": 49883
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
    "title": "Kvartalsrapport Q3 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a5e2cc4eb1aa5dacb7918657cd4a93246",
    "date": "2024-11-05",
    "period": "2024-q3",
    "form_type": "interim-report",
    "report_key": "2024:q3",
    "filename": "Delarsrapport_Q3_2024.pdf",
    "text_chars": 50324,
    "sha256": "d71acb6909f6dc0064559b9d5eada617dc7a5aa63bb83175f56d6ad761982ba0",
    "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
        "chars": 50324
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
    "title": "Kvartalsrapport Q2 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ac33a252ae1cac6377103173b7acabf2c",
    "date": "2024-08-22",
    "period": "2024-q2",
    "form_type": "interim-report",
    "report_key": "2024:q2",
    "filename": "Delarsrapport_Q2_2024.pdf",
    "text_chars": 44660,
    "sha256": "b1aba9ecf5644930cba10892b99fbd6453b3cb18fcd3bba129bfe31e5a67ade5",
    "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
        "chars": 44660
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
    "title": "Kvartalsrapport Q1 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/aacba62192026d1de39a5f33b4daf9986",
    "date": "2024-05-03",
    "period": "2024-q1",
    "form_type": "interim-report",
    "report_key": "2024:q1",
    "filename": "Delarsrapport_Q1_2024_FINAL.pdf",
    "text_chars": 41479,
    "sha256": "4bb721d5cd96b117a2187fe95d2cbeaeb4ef1620ebcc885308a87e4feba34f5d",
    "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
    "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
        "chars": 41479
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2023",
    "title": "Årsredovisning 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a2ae7c68718235fae332b816f53ab1738",
    "date": "2024-03-27",
    "period": "2023-annual",
    "form_type": "annual-report",
    "report_key": "2023:annual",
    "filename": "Vicore_Arsredovisning_2023.pdf",
    "text_chars": 269652,
    "sha256": "8cd42f435d0f31bff067af1f3f30fc1a7412f89d76ced868bea0929d79c6716a",
    "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023",
    "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
        "chars": 179110
      },
      {
        "number": 2,
        "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
        "chars": 90540
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
    "title": "Kvartalsrapport Q4 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ad4f6a640bbf90aa0f94b72149a909dbd",
    "date": "2024-02-28",
    "period": "2023-q4",
    "form_type": "year-end-report",
    "report_key": "2023:q4",
    "filename": "Bokslutskommunike_2023.pdf",
    "text_chars": 45516,
    "sha256": "f652188f84d1a7e121c4fd947d8c3929e298979d50634fa8ca98838242c02eab",
    "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
    "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
        "chars": 45516
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
    "title": "Kvartalsrapport Q3 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a0e437a99b9af6d9ca3735b061af97537",
    "date": "2023-11-02",
    "period": "2023-q3",
    "form_type": "interim-report",
    "report_key": "2023:q3",
    "filename": "Delarsrapport_Q3_2023.pdf",
    "text_chars": 43926,
    "sha256": "3344bafc5252080871c96ece9a38f5b51c9d7b3b10a360129f1a7bef78146d4d",
    "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
        "chars": 43926
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
    "title": "Kvartalsrapport Q2 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ade8c9e5626a289c75d0d5612b408bc0b",
    "date": "2023-08-24",
    "period": "2023-q2",
    "form_type": "interim-report",
    "report_key": "2023:q2",
    "filename": "Delarsrapport_April_Juni_2023.pdf",
    "text_chars": 42123,
    "sha256": "fc851ed2d2aaaac8bab7199536d85cdbc693257f10bbf79d95a307b89d767da2",
    "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
        "chars": 42123
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
    "title": "Kvartalsrapport Q1 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a4a08c7c7e1a6de7650f7cc53f699d9bf",
    "date": "2023-05-04",
    "period": "2023-q1",
    "form_type": "interim-report",
    "report_key": "2023:q1",
    "filename": "Delarsrapport_Jan_Mar_2023.pdf",
    "text_chars": 39808,
    "sha256": "8e7ec395406e329278366eab28393e92de4ec1fbc55fc025a82ed1d7356fea5b",
    "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "txt_url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
        "chars": 39808
      }
    ]
  },
  {
    "doc_id": "sec-edgar-sec-filing-odaterad-tm2619347d1-ex99-1-htm",
    "title": "SEC filing – odaterad – tm2619347d1_ex99-1.htm",
    "source": "SEC EDGAR",
    "source_class": "sec",
    "source_url": null,
    "date": null,
    "period": null,
    "form_type": "SEC filing",
    "report_key": null,
    "filename": "tm2619347d1_ex99-1.htm",
    "text_chars": 5916,
    "sha256": "64961e5e097265ef2af1cd05b553a06c33cb301a90bc3b1e3114352b56f848ad",
    "url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-tm2619347d1-ex99-1-htm",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-tm2619347d1-ex99-1-htm",
    "txt_url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-tm2619347d1-ex99-1-htm/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-tm2619347d1-ex99-1-htm/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-tm2619347d1-ex99-1-htm/part-001.html",
        "chars": 5916
      }
    ]
  },
  {
    "doc_id": "sec-edgar-sec-filing-odaterad-tm2619347d1-6k-htm",
    "title": "SEC filing – odaterad – tm2619347d1_6k.htm",
    "source": "SEC EDGAR",
    "source_class": "sec",
    "source_url": null,
    "date": null,
    "period": null,
    "form_type": "SEC filing",
    "report_key": null,
    "filename": "tm2619347d1_6k.htm",
    "text_chars": 1642,
    "sha256": "a4b3c4ea3a50c3a069277d51877c56b6ba981156cf5515175e5514aefe71d333",
    "url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-tm2619347d1-6k-htm",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-tm2619347d1-6k-htm",
    "txt_url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-tm2619347d1-6k-htm/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-tm2619347d1-6k-htm/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-tm2619347d1-6k-htm/part-001.html",
        "chars": 1642
      }
    ]
  },
  {
    "doc_id": "sec-edgar-sec-filing-odaterad-0001104659-26-080617-txt",
    "title": "SEC filing – odaterad – 0001104659-26-080617.txt",
    "source": "SEC EDGAR",
    "source_class": "sec",
    "source_url": null,
    "date": null,
    "period": null,
    "form_type": "SEC filing",
    "report_key": null,
    "filename": "0001104659-26-080617.txt",
    "text_chars": 21251,
    "sha256": "f70272844128ed42b63a29a37ead6b976b1ec8284ef3d51f7f364c78e42d901a",
    "url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-txt",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-txt",
    "txt_url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-txt/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-txt/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-txt/part-001.html",
        "chars": 21251
      }
    ]
  },
  {
    "doc_id": "sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-html",
    "title": "SEC filing – odaterad – 0001104659-26-080617-index.html",
    "source": "SEC EDGAR",
    "source_class": "sec",
    "source_url": null,
    "date": null,
    "period": null,
    "form_type": "SEC filing",
    "report_key": null,
    "filename": "0001104659-26-080617-index.html",
    "text_chars": 990,
    "sha256": "78353841bd34e4efe3f7ace681883b4f0a4912daa17b8dca12d99922e24be9b1",
    "url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-html",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-html",
    "txt_url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-html/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-html/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-html/part-001.html",
        "chars": 990
      }
    ]
  },
  {
    "doc_id": "sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-headers-html",
    "title": "SEC filing – odaterad – 0001104659-26-080617-index-headers.html",
    "source": "SEC EDGAR",
    "source_class": "sec",
    "source_url": null,
    "date": null,
    "period": null,
    "form_type": "SEC filing",
    "report_key": null,
    "filename": "0001104659-26-080617-index-headers.html",
    "text_chars": 1362,
    "sha256": "e4a85a753604717796572d2f025716220b775cf28c8f2582fee6f3c55e6048db",
    "url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-headers-html",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-headers-html",
    "txt_url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-headers-html/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-headers-html/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/sec-edgar-sec-filing-odaterad-0001104659-26-080617-index-headers-html/part-001.html",
        "chars": 1362
      }
    ]
  },
  {
    "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
    "title": "MFN bolagssida och bolagsmetadata",
    "source": "MFN",
    "source_class": "mfn",
    "source_url": "https://mfn.se/all/a/vicore-pharma-holding",
    "date": null,
    "period": null,
    "form_type": "company-page",
    "report_key": null,
    "filename": "company.txt",
    "text_chars": 12640,
    "sha256": "b777bd0383a50819bc3ab3cc52dbc206b4e1ebd155990f3f22cc745d99efbe68",
    "url": "/company/vicore-pharma-holding/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "absolute_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "txt_url": "/company/vicore-pharma-holding/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/vicore-pharma-holding/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/vicore-pharma-holding/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
        "chars": 12640
      }
    ]
  }
]